FDA Orphan Drug Designation for PLT012

Pilatus Biosciences’ lead candidate, PLT012, has been granted Orphan Drug Designation by the FDA for the treatment of hepatocellular carcinoma (HCC) and intrahepatic bile duct cancer. This designation underscores the potential of the therapy to address these rare and aggressive cancers, providing new hope for patients with limited treatment options. With this milestone, Pilatus Biosciences is advancing toward clinical trials to transform care for underserved patient populations.